



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製葯(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

(Stock code : 2348)

(股份代號: 2348)

NOTIFICATION LETTER 通知信函

22 April 2024

Dear Registered Shareholders,

Dawnrays Pharmaceutical (Holdings) Limited (the “Company”)
– Notice of Publication of 2023 Environmental, Social and Governance Report (“2023 ESG Report”)

The English and Chinese versions of the Company’s 2023 ESG Report are available on the Company’s website at www.dawnrays.com and that of Hong Kong Exchanges and Clearing Limited (“HKEx”) at www.hkexnews.hk. You may access the 2023 ESG Report by clicking “Investor Relations” on the home page of the Company’s website, then selecting “2023 Environmental, Social and Governance Report” under “Financial Reports” or browsing through the HKEXnews’ website.

The 2023 ESG Report is published in electronic form only. If you wish to receive the printed version of the 2023 ESG Report, you may send your request in writing to the Company c/o the Company’s Hong Kong branch share registrar and transfer office, Tricor Abacus Limited at 17/F Far East Finance Centre, 16 Harcourt Road, Hong Kong.

Should you have any queries in relation to this letter, please call the Customer Service Hotline of the Company’s Hong Kong branch share registrar and transfer office, Tricor Abacus Limited at (852) 2980 1333 from 9:00 a.m. to 6:00 p.m., Mondays to Fridays (excluding Hong Kong public holidays).

Yours faithfully,
For and on behalf of
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

各位登記股東：

東瑞製葯(控股)有限公司(「本公司」)
– 2023環境、社會及管治報告(「2023環境、社會及管治報告」)之發佈通知

本公司之2023環境、社會及管治報告的英文及中文版本已登載於本公司網站(www.dawnrays.com)及香港交易及結算所有限公司(「香港交易所」)網站(www.hkexnews.hk)，歡迎瀏覽。閣下可於本公司網站主頁按「投資者關係」一項，再在「業績報告」項下選擇「2023環境、社會及管治報告」或在香港交易所披露易網站瀏覽有關文件。

2023環境、社會及管治報告僅以電子形式發佈。如閣下希望收取2023環境、社會及管治報告的印刷本，可將有關請求以書面方式通知本公司之香港股份過戶登記分處卓佳雅柏勤有限公司以轉交本公司，地址為香港夏慤道16號遠東金融中心17樓。

如閣下對本函件內容有任何疑問，請於星期一至星期五(香港公眾假期除外)上午九時正至下午六時正致電本公司之香港股份過戶登記分處卓佳雅柏勤有限公司客戶服務熱線，電話號碼為(852) 2980 1333。

代表
東瑞製葯(控股)有限公司
主席
李其玲
謹啟

二零二四年四月二十二日

*For identification only 僅供識別